Chemring Reports Record £1.3bn Order Book and Strong H1 Growth Amid Defense Spending Surge
Chemring posts record £1.3bn order book, +8% H1 profit & dividend hike amid global defence spending surge. Strong sector positioning. *(156 characters)*
This article covers information on Chemring Group PLC.
LON:CHGWell, well, well. If you thought defence spending was cooling off, Chemring’s latest numbers just dropped a rather large countermeasure on that idea. Fresh from the RNS mill, this specialist in sensors, countermeasures, and energetics is reporting a record order book of £1.3 billion – up a chunky 25% year-on-year. First-half revenue ticked up 5% to £234.3m, and underlying operating profit climbed 8% to £27.1m. The interim dividend? A tidy 4% bump to 2.7p per share. Clearly, geopolitical instability is proving rather good for business.
Breaking Down the Battlefield: Key Performance Metrics
Let’s cut through the noise and focus on what matters:
- Record Order Intake & Book: £488m in new orders (up 42%) pushed the order book to £1,304m. That’s the highest in Chemring’s history. Crucially, 85% of expected FY2025 revenue is already delivered or in the order book.
- Profitability Growth: Underlying EBITDA rose 12% to £39.8m. The underlying operating profit margin improved to 11.6% (H1 2024: 11.2%), showing operational efficiency gains.
- Investment Mode: Capex hit £46.1m as they plough cash into expanding capacity, especially in energetics. Net debt rose to £93.3m (H1 2024: £75.3m), but remains very manageable at 0.95x underlying EBITDA.
- Shareholder Returns: Interim dividend up 4% to 2.7p. £3.3m deployed so far into the £40m share buyback programme announced in February.
Why the Surge? Riding the Defence Spending Wave
CEO Michael Ord didn’t mince words: “Growing geopolitical uncertainty resulting in increased defence expenditure, particularly across NATO” is the rocket fuel here. The numbers scream it:
- The war in Ukraine (entering its 4th year) and Middle East tensions are forcing European nations to re-arm rapidly.
- The UK’s new Strategic Defence Review (SDR) commits to boosting defence spending to 2.5% of GDP by 2027, building new munitions factories, and investing heavily in next-gen tech like AI and electronic warfare – areas where Chemring plays.
- The EU’s Readiness 2030 initiative aims to mobilise up to €800 billion for defence.
- The US remains the world’s largest defence market, with a $1.01 trillion budget request for FY26 focused on countering threats like China’s missile capabilities.
Chemring isn’t just a spectator; it’s a critical supplier embedded in these national security priorities.
Sector Deep Dive: Countermeasures & Energetics (The Powerhouse)
This segment is absolutely firing:
- Revenue: £141.7m (+20%)
- Underlying Operating Profit: £20.4m (Margin: 14.4% vs 10.0% H1 2024)
- Order Intake: £418m (+68%) – driven by massive contracts for specialist energetic materials.
Standout Wins:
- A 12-year framework agreement with Diehl Defence (Germany) for MCX energetic material, including an initial €231m order.
- A £36m, 3-year HMX supply deal with SAAB Switzerland.
- A £23m order for critical NLAW (Next Generation Light Anti-Tank Weapon) components in the UK.
- A $106m order from a major US missile programme.
The £200m investment programme (partly funded by a £90m Norwegian grant) to expand energetic materials capacity is on track, aiming to add £100m annual revenue and £30m operating profit from 2028. Feasibility studies for further plants in Norway and Scotland are underway. The order book here is a fortress: £1,222m, covering 96% of expected 2025 revenue, 86% of 2026, and 64% of 2027.
Sector Deep Dive: Sensors & Information (Temporary Pause, Big Future)
Performance was softer, but largely expected and strategic:
- Revenue: £92.6m (-12%)
- Underlying Operating Profit: £16.1m (Margin: 17.4% vs 20.4% H1 2024)
- Order Intake: £70m (H1 2024: £96m)
Why the dip? Primarily delays in the UK’s SDR publication slowed new order placement at Roke (Chemring’s tech hub). Management proactively restructured, integrating the Futures unit and reducing headcount by ~50 (cost: £1.5m non-underlying).
Bright Spots & Future Gunsights:
- STORM Contract: Secured a massive £251m, 6-year framework to lead a UK industry consortium on missile defence with the UK Missile Defence Centre (UK MDC). A huge strategic win.
- US Defence: Progress on key biological detection programmes (EMBD, JBTDS).
- New Tech: Launched EM-Vis Deceive (portable EW system) and signed a partnership with Kagai Corp for the Japanese market.
With the SDR now published, H2 demand is expected to rebound. Roke is central to UK priorities like the £1bn “digital targeting web” and the new Cyber and Electromagnetic Activities (CEMA) Command. The ambition remains organic growth to >£250m revenue by 2028.
Financial Fortress & Strategic Ambition
Chemring isn’t just weathering the storm; it’s building battleships:
- Refinanced: Secured a £180m revolving credit facility until 2028 (with extensions), plus existing facilities, totalling £275m available liquidity. Covenant headroom is strong (leverage: 0.97x; interest cover: 13.94x).
- Pension: The buy-in process for the legacy UK scheme continues towards eventual buy-out.
- 2030 Vision: The goal of reaching £1bn annual revenue by 2030 remains firmly on track. This assumes market growth, successful capacity expansion, and selective bolt-on M&A (particularly in cyber, information advantage, and US space/missile sub-systems).
The Bottom Line: Defence Pays
Chemring’s H1 paints a picture of a business perfectly positioned in a sector with powerful, long-term tailwinds. The record order book provides exceptional near-term visibility, while strategic investments in capacity (especially in energetics) lay the groundwork for sustained growth beyond 2027. The slight pause in Sensors & Information looks temporary, overshadowed by the colossal STORM win and Roke’s alignment with critical UK defence tech priorities.
With disciplined capital allocation (dividend growth, buybacks, targeted capex), a robust balance sheet, and a clear path to £1bn revenue, Chemring offers investors a compelling way to gain exposure to the structural growth in global defence and security spending. As CEO Ord succinctly put it, the Group is “well positioned, with a strong and sustainable platform” for the future. In today’s uncertain world, that platform looks increasingly valuable.
Related
Keep reading
Investing
SEGRO trading update shows stronger rents, occupancy and development demand
SEGRO contracted £70 million of new headline rent, lifted occupancy to 94.7% and maintained a strong balance sheet during 2026.
JoshuaOctober 21, 2026
Investing
Is October Really a Dangerous Month for Stock Markets?
October has a fearsome reputation among investors. History explains why, but it does not provide a reliable market-timing strategy. Here is a more useful way to think about seasonality, volatility and portfolio risk.
JoshuaOctober 19, 2026
Investing
Should You Sell ESPP Shares Immediately? A Practical Framework
Selling shares immediately after an employee stock purchase plan purchase can capture the discount while limiting employer-stock risk. But fees, tax and small transaction sizes can change the maths.
JoshuaOctober 19, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.